A.U. SABITOV¹, A.V. MARAKULINA²

 ¹ Ural State Medical University of the Ministry of Health of the Russian Federation, Yekaterinburg

² Children’s City Clinical Hospital № 9, Yekaterinburg

 Contact details:

Sabitov A.U. — MD., Professor, Vice Rector on pre-matriculation and post-graduate training, Head of the Department of Infectious Diseases and Clinical Immunology

Address: 3 Repin St., Yekaterinburg, Russian Federation, 620028, tel.: +7 (343) 214-86-69, e-mail: postdiplom@usma.ru

In the structure of morbidity in preschool children, the leading position remains for recurrent respiratory diseases. The fact of the synergistic action of recurring episodes of acute respiratory diseases, their severity and the presence of allergic sensitization on the control of the course of bronchial asthma is indisputable.

The purpose — to study the prolonged protective effect of the prophylactic immune-mediated antiviral drug based on technologically processed antibodies in high solutions for resistance to acute respiratory diseases in the selected patient groups.

Material and methods. A retrospective analysis of the medical documentation of 71 preschool-age patients with bronchial asthma was performed for resistance to acute respiratory diseases.

Results. The use of a four-month prophylactic course of the antiviral drug during the period of epidemiological trouble for acute respiratory diseases with the transformation of its dosage regimen according to indications made it possible to reduce the frequency and severity of episodes of recurrent respiratory diseases and the frequency of antibacterial drugs taking, as wellas to reduce the number of exacerbations of bronchial asthma caused by respiratory viruses. The result of improved control of bronchial asthma was a reduction of the basic therapy of bronchial asthma in 76,2% of patients. No significant prolonged therapeutic and prophylactic effect was observed after its withdrawal.

Key words: recurrent respiratory infections, bronchial asthma, antiviral therapy.

REFERENCES

1. Velikoretskaya M.D. Recurrent respiratory infections in children. Meditsinskiy sovet, 2017, no. 9, pp. 124–130 (in Russ.).
2. Kosenko I.M. Recurrent respiratory infections in children: modern approaches to rational pharmacotherapy. Pediatriya, 2018, no. 1, pp. 51–56 (in Russ.). DOI:10.26442/2413-8460_2018/1/51-56
3. Okhotnikova E.N., Rudenko S.N., Kolomiets E.N. Recurrent infections of the respiratory tract in children and their immunoprophylaxis in the light of modern concepts of the immunomodulatory activity of immunotropic drugs. Sovremennaya pediatriya, 2013, no. 1 (49), pp. 42–50 (in Russ.).
4. Baranov A.A., Lobzin Yu.V., Namazova-Baranova L.S., Tatochenko V.K., Uskov A.N., Kulichenko T.V. et al. Acute respiratory viral infection in children: modern approaches to diagnosis and treatment . Pediatricheskaya farmakologiya, 2017, no. 14 (2), pp. 100–107 (in Russ.).
5. Ministry of Health of the Russian Federation. Department of Monitoring, Analysis and Strategic Development of Healthcare of the Federal State Budgetary Institution «Central Research Institute for Health Organization and Information» of the Ministry of Health of the Russian Federation. The incidence of the child population in Russia (0-14 years) in 2017: statistical materials, part 5, pp. 100–103 (in Russ.), available at: https://www.rosminzdrav.ru/documents/9479-statisticheskaya-informatsiya-za-2017
6. Levina A.S., Babachenko I.V., Skripchenko N.V. Etiological structure of diseases in frequently ill children depending on age. Rossiyskiy vestnik perinatologii i pediatrii, 2017, no. 62 (2), pp. 72–77 (in Russ.).
7. Kurkina A.I., Klimenko K.E. Modern aspects of pharmacotherapy and prevention of ARVI. Meditsinskiy sovet, 2015, no. 1, pp. 95–102 (in Russ.).
8. Natsional’naya programma «Bronkhial’naya astma u detey. Strategiya lecheniya i profilaktika», pod red. Volkova I.K., Geppe N.A., Kondyurinoy E.G. [National program «Bronchial asthma in children. Treatment strategy and prevention ”, ed. Volkov I.K., Geppe N.A., Kondyurina E.G.]. Moscow, 2012.
9. Global Initiative for Asthma. 2018 GINA Report, Global Strategy for Asthma Management and Prevention, available at: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention
10. Macharadze D.Sh. Asthma and viral infections in children. Voprosy sovremennoy pediatrii, 2014, no. 13 (1), pp. 124–128 (in Russ.).
11. Fassakhov R.S. Modern pharmacotherapy of bronchial asthma: priorities in achieving control regardless of severity. Russkiy meditsinskiy zhurnal, 2017, no. 25 (3), pp. 221–226 (in Russ.).
12. Fedorov I.A. Analysis of clinical, anamnestic and laboratory data in children with asthma and children with a risk of asthma development. Selected Papers of the International Scientific School «Paradigma». 2016. Pp. 24–31.
13. Geppe N.A., Revyakina V.A. New international recommendations for bronchial asthma in children PRACTALL. Atmosfera. Pul’monologiya i allergologiya, 2008, no. 1, pp. 60–67 (in Russ.).
14. Namazova–Baranova L.S. Uncontrolled bronchial asthma in children. Pediatricheskaya farmakologiya, 2009, no. 6 (4), pp. 106–111 (in Russ.).
15. Rozenberg V.Ya. Age dynamics of hemogram indicators and immune status in children of different ages. Meditsinskaya immunologiya, 2011, no. 2–3, pp. 261–266 (in Russ.).
16. Bulatova E.M., Bogdanova N.M., Gabrusskaya T.V. Immunity: traditional concepts and new data on the formation of the immune response in ontogenesis. Pediatricheskaya farmakologiya, 2008, no. 5, pp. 79–87 (in Russ.).
17. Vel’tishchev Yu.E. Ontogenesis of the immune system and factors affecting the immunobiological reactivity of the child’s body. Voprosy okhrany materinstva i detstva, 1989, no. 10, pp. 3–12 (in Russ.).
18. Vasil’ev A.N. The use of super low doses of antibodies to interferon gamma in the treatment and prevention of viral infections. Antibiotiki i khimioterapiya, 2008, no. 53 (1), pp. 32–35 (in Russ.).
19. Zaplatnikov A.L., Burtseva E.I., Shamray L.M., Noskova T.N., Shevchenko E.S. Therapeutic effect and prevention of acute respiratory infections when using repeated courses of endogenous interferon in children. Pediatriya, 2009, no. 88 (6), pp. 111–115 (in Russ.).
20. Nikiforov V.V., Ruzhentsova T.A. Clinical efficacy and safety of Ergoferon for influenza and other acute respiratory viral infections: a critical assessment from the standpoint of evidence-based medicine. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2019, no. 8 (4), pp. 84–97 (in Russ.). DOI: 10.24411/2305-3496-2019-14011
21. PRIMA: pediatricheskie rekomendatsii po immunomoduliruyushchim preparatam v ambulatornoy praktike (konsensus) [PRIMA: pediatric recommendations for immunomodulatory drugs in outpatient practice (consensus)]. Moscow: RG-Press, 2017. P. 80.
22. Geppe N.A., Lyskina G.A., Vinogradova O.I. Retrospective assessment of the experience of using anaferon for the prevention and treatment of acute respiratory viral infections in children from risk groups undergoing inpatient treatment. Pediatriya, 2009, no. 5 (56), pp. 16–20 (in Russ.).
23. Instruktsiya Farmakologicheskogo komiteta MZ i SR RF po meditsinskomu primeneniyu preparata «Ergoferon» [Instruction of the Pharmacological Committee of the Ministry of Health and the Russian Federation on the medical use of the drug «Ergoferon»]. LRS-007362/10-290710; RK-LS-5№020791.
24. Ershova A.V., Sabitov A.U. Optimization of ARVI treatment in children with bronchial asthma. Prakticheskaya meditsina, 2015, no. 2 (87), pp. 85–90 (in Russ.).
25. Ershova A.V., Sabitov A.U. Preventive and therapeutic efficacy of ergoferon in viral-induced bronchial asthma. Zhurnal infektologii, 2015, no. 4, pp. 71–72 (in Russ.).
26. Khalafyan A.A. STATISTICA 6. Statisticheskiy analiz dannykh [STATISTICA 6. Statistical data analysis]. Moscow: Binom, 2008.